Chk1 activation attenuates sensitivity of lapatinib in HER2‐positive gastric cancer. (14th May 2018)

• Record Type: Journal Article
• Authors: Bai, Ming; Song, Na; Che, Xiaofang; Wang, Xiaoxun; Qu, Xiujuan; Liu, Yunpeng
• Is Part Of: Cell biology international. Volume 42:Number 7(2018)
• Page Start: 781
• Page End: 793
• Publication Date: 2018-05-14
• Subjects: ATR -- Chk1 -- gastric cancer -- HER2 -- lapatinib -- sensitivity; Cytology -- Periodicals; Cells -- Periodicals; 571.605
• DOI: 10.1002/cbin.10922
• Languages: English
• ISSNs: 1065-6995

Abstract

Abstract: The ATM and Rad3‐related (ATR)/checkpoint kinase 1 (Chk1) pathway plays a pivotal role in DNA damage sensor and modulating homologous recombination. Recently, emerging evidence demonstrated that Chk1 phosphorylation was associated with chemotherapy and radiotherapy resistance. In this study, we explored the effect of ATR/Chk1 pathway on regulating lapatinib sensitivity in human epidermal growth factor receptor‐2 (HER2)‐positive gastric cancer cell lines. We selected two HER2‐positive gastric cancer cell lines, and NCI‐N87 cells exhibited higher sensitivity than MKN7 cells. Application of lapatinib inhibited phosphorylated HER2 and EGFR and the formation of epidermal growth factor receptor (EGFR)/HER2 complex in both cells. In NCI‐N87 cells, lapatinib induced G1 arrest and reduced Chk1 phosphorylation through inhibiting the expression of DNA topoisomerase 2‐binding protein 1 (TopBP1). While in MKN7 cells, no significant cell cycle transition was found and phosphorylated Chk1 was mildly upregulated. Inhibition of Chk1 phosphorylation enhanced the lapatinib sensitivity of MKN7 cells, which was shown by potentiated anti‐proliferative effect, G1 arrest, downregulation of phosphorylated AKT and ERK along with aggravated DNA damage. In addition, increased Chk1 phosphorylation in NCI‐N87 cells attenuated lapatinib‐induced anti‐proliferative effect and G1 arrest, and abrogated reduced phosphorylated AKT and ERK. Taken together, our study provides a novel mechanism for regulating lapatinib sensitivity in HER2 positive gastric cancer cells, suggesting a new strategy in clinical treatment.